Get the Stockscreener App
4.995
1.89%
0.095
Evolus Inc stock is traded at $4.995, with a volume of 641.51K.
It is up +1.89% in the last 24 hours and down -30.56% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$4.90
Open:
$4.94
24h Volume:
641.51K
Relative Volume:
0.48
Market Cap:
$323.45M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-4.625
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-0.15%
1M Performance:
-30.56%
6M Performance:
-47.83%
1Y Performance:
-64.67%
1-Day Range:
$4.88
$5.10
1-Week Range:
$4.81
$5.24
52-Week Range:
$4.7401
$17.12
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
4.99 | 317.62M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus (NASDAQ:EOLS) Given New $13.00 Price Target at BTIG Research - MarketBeat
EOLS: BTIG Lowers Price Target While Maintaining Buy Rating | EO - GuruFocus
Understanding Momentum Shifts in (EOLS) - Stock Traders Daily
BTIG lowers Evolus stock price target to $13 on aesthetic market decline By Investing.com - Investing.com South Africa
BTIG lowers Evolus stock price target to $13 on aesthetic market decline - Investing.com
Evolus projects robust 2025 growth with upcoming product launches - MSN
Panic Selling: Should you avoid Evolus Inc stock right nowEarnings Performance Report & Capital Efficient Trade Techniques - baoquankhu1.vn
Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop - 富途牛牛
VIX Spike: Is Evolus Inc undervalued by DCF analysis2025 Market WrapUp & Safe Entry Trade Reports - baoquankhu1.vn
Stifel Analyst Lowers Price Target on Evolus (EOLS) to $17.00 | - GuruFocus
Stifel lowers Evolus stock price target to $17 on tempered growth outlook - Investing.com Australia
Stifel lowers Evolus stock price target to $17 on tempered growth outlook By Investing.com - Investing.com South Africa
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (EOLS) Movement - Stock Traders Daily
Evolus reports 15% Q4 growth, projects 2026 profitability By Investing.com - Investing.com Nigeria
Evolus sees FY26 revenue $327M-$337M, consensus $351.66M - TipRanks
Evolus sees Q4 revenue $88.6M-$90.6M, consensus $90.91M - TipRanks
Evolus, Inc. (EOLS) Stock Analysis: Unpacking a 222% Potential Upside in the Aesthetic Market - DirectorsTalk Interviews
EOLS: HC Wainwright & Co. Reiterates Buy Rating with $20 Price T - GuruFocus
Evolus' (EOLS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Evolus (EOLS) Projects Strong Revenue Growth Through 2028 - GuruFocus
EOLS Projects Strong Revenue Growth with Key Product Line - GuruFocus
Evolus (EOLS) Achieves Sixth Year of Double-Digit Growth in 2025 - GuruFocus
EOLS Projects Optimistic Growth with Strategic Market Expansion - GuruFocus
Evolus outlook FY sales USD 327-337 million - marketscreener.com
Evolus reports 15% Q4 growth, projects 2026 profitability - Investing.com
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue - Business Wire
How Evolus Inc. stock valuations compare to rivalsMarket Growth Review & Stock Timing and Entry Methods - Улправда
Does Evolus Inc. stock trade at a discount to peersChart Signals & Reliable Breakout Forecasts - Улправда
Why Evolus Inc. stock is favored by top institutions2025 Performance Recap & Expert Curated Trade Setup Alerts - Улправда
Can Evolus Inc. stock deliver strong Q4 earningsSwing Trading Ideas & Small Budget Portfolio Growth - Улправда
Insider Sellers Might Regret Selling Evolus Shares at a Lower Price Than Current Market Value - simplywall.st
Mizuho cuts Evolus (EOLS) estimates for Jeuveau/Evolysse on waning consumer sentiment and inflationary pressure on elective aesthetics - MSN
Will Evolus Inc. (EVL) stock benefit from sector leadershipRisk Mitigation Techniques & Low Entry Cost Investments - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS) - The Globe and Mail
Discipline and Rules-Based Execution in EOLS Response - Stock Traders Daily
Avelar Rui, Evolus officer, sells $16k in EOLS stock By Investing.com - Investing.com India
Evolus CEO Moatazedi sells $75k in shares By Investing.com - Investing.com Australia
Evolus CEO Moatazedi sells $75k in shares - Investing.com
Avelar Rui, Evolus officer, sells $16k in EOLS stock - Investing.com
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 10,539 Shares of Stock - MarketBeat
Rui Avelar Sells 2,261 Shares of Evolus (NASDAQ:EOLS) Stock - MarketBeat
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Motley Fool
Evolus, Inc. $EOLS Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
Big Picture: Does Evolus Inc stock trade at a discount to peersPortfolio Update Summary & AI Powered Buy and Sell Recommendations - moha.gov.vn
Evolus' (EOLS) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Needham Reiterates Evolus (EOLS) Hold Recommendation - Nasdaq
Needham Reiterates Hold Rating for Evolus (EOLS) | EOLS Stock Ne - GuruFocus
Net current asset value per share of Evolus, Inc. – BER:EVL - TradingView — Track All Markets
Trading the Move, Not the Narrative: (EOLS) Edition - Stock Traders Daily
EV Market: Why Evolus Inc. stock is a must watch in 2025Earnings Growth Summary & Consistent Return Investment Signals - Улправда
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evolus Inc Stock (EOLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Avelar Rui | See Remarks |
Dec 22 '25 |
Sale |
7.15 |
2,261 |
16,168 |
356,821 |
| Yamagishi-Dressler Tomoko | Chief Marketing Officer |
Aug 22 '25 |
Sale |
7.51 |
5,722 |
42,972 |
89,949 |
| Stewart Brady | Director |
Aug 15 '25 |
Buy |
6.82 |
30,000 |
204,486 |
88,629 |
| MOATAZEDI DAVID | See Remarks |
Jun 13 '25 |
Sale |
10.05 |
111,323 |
1,119,141 |
381,509 |
| MOATAZEDI DAVID | See Remarks |
Jun 16 '25 |
Sale |
9.89 |
16,582 |
164,054 |
364,927 |
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):